Bustling Stock in Focus: Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)

A number of other brokerages have also recently commented on SGYP. Recently, shares of Synergy Pharmaceuticals Inc. Below is a list of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) latest ratings and price target changes. The company has an average rating of “Hold” and an average target price of $11.50. Rodman & Renshaw reaffirmed a “buy” rating and issued a $18.00 price target on shares of Synergy Pharmaceuticals in a report on Wednesday, March 29th. Zacks Investment Research cut Synergy Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd. Analysts have a mean recommendation of 2.00 on this stock (A rating of less than 2 means buy, “hold” within the 3 range, “sell” within the 4 range, and “strong sell” within the 5 range). (NASDAQ:SGYP). At the time of writing, the First Call consensus price target for the company is $10.44.

Synergy Pharmaceuticals (NASDAQ:SGYP) traded down 3.117% during mid-day trading on Wednesday, reaching $3.575. The stock’s price moved up its 200-day moving average of $51.98. The company has market cap of $76.43 million. Tudor Investment Corp Et Al boosted its position in shares of Synergy Pharmaceuticals by 1.3% in the fourth quarter. The stock has earnings growth of 41.20% yoy and showed a low EPS growth of -31.80% over the past five years. The biopharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.07. The firm had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.10 million. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 24.44% since May 29, 2016 and is uptrending. Ellington Management Group LLC boosted its position in shares of Synergy Pharmaceuticals by 65.0% in the fourth quarter. Asymmetry Capital Management L.P. now owns 339,068 shares of the biopharmaceutical company’s stock valued at $1,868,000 after buying an additional 40,878 shares during the period. Ellington Management Group LLC now owns 19,300 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 7,600 shares during the last quarter.

Director, BRANCACCIO JOHN P, sold 2,518 common shares of Synergy Pharmaceuticals Inc. Perceptive Advsrs Ltd Com holds 0.21% or 490,300 shares in its portfolio. BlackRock Advisors LLC raised its position in Synergy Pharmaceuticals by 60.5% in the third quarter. Stifel Financial Corp now owns 30,289 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 7,750 shares during the last quarter. Great Point Partners LLC bought a new position in Synergy Pharmaceuticals during the third quarter worth about $35,386,000. However the company reported $-0.23 earnings per share for the same quarter during a year ago. Everyone wants to see their stock picks soar, but the stark reality is that during a market wide sell-off, this may not be the case.

Synergy Pharmaceuticals Inc.is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Firm is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders. RSI can also be used to identify the general trend. Invest in simplicity: You should invest in businesses which you understand.

ROI deals with the invested cash in the company and the return the investor realize on that money based on the net profit of the business.

New investors may sometimes be working with limited capital. Spread out: Markets are volatile in nature. Economic growth: Higher economic growth or better prospects for growth will help firms be more profitable because there will be more demand for goods and services. EPS breaks down the profitability of the company on a single share basis. Lower interest rates: Lower interest rates can make shares more attractive for two reasons. The firm has “Buy” rating by TH Capital given on Thursday, October 29. Ameritas Invest holds 15,667 shares. A stock price loss will yield a negatively weighted alpha. They will also dislike political instability which may make it hard to pursue strong economic policies. If they receive bad news they will sell. Investors are always trying to predict the future. They now have a Dollars 13 price target on the stock. The stock added 1.99% beyond one week and declined -1.47% during previous one month session. When prices fall, people may feel the need to follow suit and get out of the market. Nuveen Asset Lc accumulated 11,357 shares or 0% of the stock.

Leave a Reply

Your email address will not be published. Required fields are marked *